Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3374 - M-bioscore: a practical tool for predicting outcomes among patients with previously untreated metastatic breast cancer.

Date

11 Sep 2017

Session

Poster display session

Topics

Breast Cancer

Presenters

Omar Abdel-Rahman

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

O. Abdel-Rahman

Author affiliations

  • Clinical Oncology, Ain Shams University Faculty of Medicine, 11566 - Cairo/EG
More

Resources

Abstract 3374

Background

Two prognostic models “bioscore” and “Neo-bioscore” were recently published and validated to help predict the outcomes of patients with non-metastatic breast cancer treated with either upfront surgery or upfront neoadjuvant chemotherapy. A comparable model for metastatic disease is yet to be developed. The current study thus sought to propose and validate a third model “M-bioscore” to help predict the outcomes of treatment-naïve patients with metastatic breast cancer.

Methods

Through SEER*Stat program, surveillance, epidemiology and end results (SEER) database (2010-2013) was accessed. The resulting cohort was equally split into two halves: training set (to guide model development) and validation set (to test the model prediction). Multivariate analysis for the candidate prognostic factors (extent of metastases, estrogen receptor (ER), progesterone receptor (PR), HER2 neu and nuclear grade) was conducted through a Cox proportional model. M-bioscore was then calculated for each patient. Cancer-specific survival analyses according to M-bioscore were conducted through Kaplan-Meier analysis/log-rank testing.

Results

A total of 6655 patients with previously untreated metastatic breast cancer and complete data were identified in the period from 2010-2013. The following factors were associated with better cancer-specific survival in multivariate analysis in the training set (isolated distant nodal metastases, ER positivity, PR positivity, HER 2 neu positivity and lower nuclear grade) (P 

Conclusions

M-bioscore is a novel, easy and reliable tool for predicting the outcomes of patients with previously untreated metastatic breast cancer. Further external validation within the context of other population-based cohorts is recommended.

Clinical trial identification

Legal entity responsible for the study

Omar Abdel-Rahman

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.